KRAS and non-small cell lung carcinoma: Michaelidou et al. recently supported this study by detecting the KRAS G12/G13 variant in the plasma ctDNA of NSCLC patients in first-line systemic treatment, which was significantly associated with poor patient disease outcomes, in terms of PFS and OS, serving as an independent biomarker of unfavorable prognosis in NSCLC patients [139].